What Cinqaero Treats: Main Uses and Benefits

Targeting Severe Eosinophilic Asthma and Uncontrolled Disease

Cinqaero is a specialized, add-on maintenance therapy used in adult patients with the severe eosinophilic phenotype of asthma. It is commonly used for the management of this condition and is relevant in clinical settings marked by increased discomfort or tension when asthma symptoms and disease activity remain inadequately controlled despite standard high-dose treatments. The therapy addresses conditions involving inflammatory or irritative processes that characterize this severe form of respiratory disease. Its role is applied across domains where additional symptomatic support is needed, including for severe asthma, recurrent asthma exacerbations, and persistent airflow limitation.

“Cinqaero supports patients by helping to ease the overall symptom burden associated with symptoms associated with acute or episodic changes.”

Supporting Lung Function and Daily Breathing Comfort

The therapy helps address symptom clusters that may become intense or disruptive, such as the rate of severe asthma exacerbations, and may assist with managing symptoms that create noticeable physiological strain, potentially supporting improved lung function. This support is generally relevant for patients with a history of recurrent attacks that frequently necessitate treatment with systemic corticosteroids. For the patient, this contributes to improved day-to-day comfort and stability during symptomatic periods.

---

Quick Fact: Support for Symptoms Associated with Severe Asthma Cinqaero is used to help manage the frequency and severity of asthma attacks that require urgent medical attention, supporting patients during difficult episodes by easing distress and contributing to easing the overall symptom load.

Regulatory References

1. European Medicines Agency (EMA) summary

Eligibility: Who Can and Cannot Use Cinqaero (Reslizumab)

The eligibility for Cinqaero is strictly defined by regulatory authorities based on age, disease type, and pre-existing conditions.

Populations Allowed and Contraindicated

Category	Eligibility Status (Official Labeling)
Approved Population	Adult patients (18 years and older) with severe eosinophilic asthma requiring add-on maintenance therapy.
Absolute Contraindication	Patients with known hypersensitivity to reslizumab or any of its excipients.
Use Not Indicated	The medicine is not indicated for the relief of acute bronchospasm or status asthmaticus, nor for other eosinophilic conditions.

Age and Condition Restrictions

Regulatory documents state that the safety and efficacy have not been established for patients younger than 18 years of age. Use in pediatric populations is not indicated. For older adults, limited data is available for patients over 75 years of age.

Use is conditional for some comorbidities: patients with a pre-existing parasitic (helminth) infection must be treated prior to initiating therapy. While no dose adjustment is required for hepatic or renal impairment, the medicine has not been studied in patients with severe renal impairment or end-stage renal disease.

Pregnancy and Lactation

Use during pregnancy is preferably to be avoided as a precautionary measure due to limited data. It is unknown whether reslizumab is excreted in human milk, and a risk to the suckling child cannot be excluded during the first few days after birth.

The regulatory interaction profile for reslizumab, a monoclonal antibody, is structured around its biological nature, which dictates its clearance pathway and necessary administration rules.

Pharmacokinetic and Metabolic Interactions

Due to its structure, reslizumab is cleared through enzymatic degradation, similar to endogenous proteins, and is not metabolized by the cytochrome P450 (CYP) enzyme system. Therefore, based on in vitro data, it is officially considered unlikely to affect the activity of key CYP enzymes like CYP1A2, CYP3A4, or CYP2B6. Population pharmacokinetic analysis has established that co-administration of other common asthma therapies, such as systemic corticosteroids and leukotriene antagonists, does not affect the systemic exposure of reslizumab. No formal interactions with food, alcohol, or supplements are documented in official prescribing information.

Administration and Specific Co-Use Restrictions

A procedural constraint is mandated for administration: the solution must not be infused concomitantly in the same intravenous line with any other medicinal products. The safety and efficacy of reslizumab remain unstudied in patients concurrently receiving live vaccines or immunosuppressant medicinal products other than oral corticosteroids. Official labeling notes that patients with pre-existing helminth (parasitic) infections should be treated before starting therapy. No dosage adjustments are required based on age, gender, race, or the presence of mild renal or hepatic impairment.

Targeted Neutralization of Interleukin-5 (IL-5)

Cinqaero (Reslizumab) is a humanized monoclonal antibody that functions as an antagonist by binding directly to the soluble Interleukin-5 (IL-5) cytokine. This high-affinity binding action neutralizes IL-5, preventing it from activating its specific receptor ( IL-5Ralpha) found on eosinophils. This molecular blockade is the initial step in the cascade that limits the activity of the key signaling protein.

---

Selective Suppression of Eosinophil Homeostasis

By removing the IL-5 signal, which is essential for eosinophil survival and maturation, the drug inhibits the differentiation and proliferation of precursor cells and accelerates the apoptosis (programmed cell death) of mature eosinophils. The primary physiological consequence of this cellular effect is a rapid and sustained systemic eosinopenia (a significant reduction in circulating eosinophil numbers).

---

Reduction of Eosinophil-Mediated Effector Activity

The systemic clearance of eosinophils functionally reduces their peripheral tissue infiltration and persistence. This diminished cellular presence subsequently minimizes the release of toxic granule proteins and inflammatory mediators into the tissue environment. This mechanism results in a reduction of chronic cellular activity and the influence of cytotoxic agents on tissue structures.

Cinqaero (reslizumab) is administered as an add-on maintenance treatment for severe eosinophilic asthma. The drug is used as an intravenous (IV) infusion. It must not be administered via any other route, such as subcutaneous or intramuscular injection, nor should it be given as an IV push or bolus.

The standard dose is determined by the patient's weight, with a recommended dosage of 3 milligrams per kilogram (3 mg/kg) of body weight. This calculated dose is delivered on a fixed, intermittent schedule of once every four weeks. Cinqaero is intended for use as a long-term therapy, with the continuation of treatment typically re-assessed at least annually. If a dose is missed, it should be resumed as soon as possible on the regular four-week schedule.

Administration must occur in a healthcare setting under professional supervision. Before infusion, the concentrate must be diluted into 50 mL of 0.9% Sodium Chloride Injection. The infusion is delivered over a fixed time range, generally lasting between 20 and 50 minutes, and requires the use of an in-line 0.2 micron filter. Specific handling constraints include the instruction to not shake the concentrate vial and to not mix the solution with any other medicinal products in the same IV line. For specific populations, no dose adjustment is required for older adults (those 65 years and over) or for adult patients with renal impairment.

Research evidence / Overview of studies for Cinqaero

Research Supporting Use in Severe Eosinophilic Asthma

The core clinical evaluation programs for Cinqaero was studied for adults whose severe eosinophilic asthma was not adequately managed despite being on high-dose inhaled corticosteroids along with other maintenance therapy. Research primarily consisted of large-scale, international, randomized, double-blind, placebo-controlled Phase 3 trials designed to run for 52 weeks, or about one year.

These studies were specific, examining only patients who met a biomarker threshold, meaning they had a high blood eosinophil count (at least ge 400 cells/mu L). Researchers monitored these defined populations to explore how symptoms change over time and how treatment affects systemic or functional imbalance over the course of the study. Findings describe patterns observed in the studies related to outcomes describing episodic or acute changes. Studies also examined subgroups, including those patients who were dependent on high doses of oral corticosteroids (OCS) due to the severity of their asthma.

---

Outcomes Measured in Clinical Trials

The main research monitored several key areas to evaluate the experiences of the observed populations. Research examined outcomes related to episodic or acute changes, primarily focusing on the annual frequency of clinical asthma exacerbations (often called asthma attacks). This outcome monitors phases of heightened symptom activity that may necessitate urgent medical attention.

Studies also explored changes in lung function, with researchers measuring the Forced Expiratory Volume in 1 second ( FEV1). Furthermore, the evidence highlights what is known about patient-reported experiences, using standardized questionnaires to assess asthma control ( ACQ) and health-related quality of life ( AQLQ). Research also describes patterns related to biomarkers (biological measures); data show patterns related to a change in blood eosinophil levels in the observed population.

---

Evidence Gaps and Areas of Research Uncertainty

Evidence is limited for long-term outcomes, as the pivotal trials and subsequent extensions did not monitor the effects over many years. This means there is limited information about very long-term outcomes or the duration of benefit after treatment is stopped. The research primarily focused on patients with a high eosinophil count, meaning that data for certain groups remain insufficient, and existing studies provide limited insight into outcomes in patients with lower blood eosinophil counts. Research also describes long-term eosinophil changes in the general patient population, but these aspects are not fully characterized.

Common questions about Cinqaero (FAQ)

Q: What is the main reason Cinqaero is prescribed for asthma?

Official labeling states that Cinqaero is an add-on maintenance treatment for adults with severe eosinophilic asthma. It is used when the asthma is not adequately controlled despite high-dose standard maintenance therapy, such as inhaled corticosteroids.

Q: How is Cinqaero different from other biologic treatments for asthma?

Cinqaero is classified as a humanized monoclonal antibody, a type of biologic medicine that works by specifically targeting and neutralizing Interleukin-5 (IL-5). Regulatory documents indicate that its safety and efficacy profile have not been established when used in combination with other biologic treatments for asthma.

Q: If a person misses an infusion, what does official guidance say?

If a dose is missed, the official guidance states that the infusion may be resumed as soon as possible. Following the resumed dose, the regular four-weekly administration schedule should be maintained.

Q: What does the research say about Cinqaero use during pregnancy?

Due to limited data available, official guidelines state that Cinqaero use during pregnancy is preferably avoided as a precautionary measure. An active pregnancy surveillance program is used to monitor outcomes for women who are exposed to the drug while pregnant.

Q: Can Cinqaero be stopped if asthma symptoms improve significantly?

Cinqaero is officially intended for use as a long-term treatment option. The decision to continue or discontinue the therapy is typically re-assessed at least annually by a healthcare professional based on the assessment of disease control.

Q: Do people with mild asthma ever use Cinqaero?

According to regulatory documents, Cinqaero is indicated only as an add-on maintenance treatment for adults with severe eosinophilic asthma. Its use is not indicated for patients who have mild asthma.

Q: Does Cinqaero cause weight gain?

Weight gain is not listed as a Common, Uncommon, or Rare stand-alone adverse reaction in the official prescribing information for Cinqaero.

Q: Can Cinqaero affect your sleep or cause insomnia?

Sleep disorders or insomnia are not listed as Common, Uncommon, or Rare stand-alone adverse reactions in the official prescribing information for Cinqaero.

Q: Are there any long-term side effects that have been studied?

Cinqaero is intended for long-term use, but the core clinical studies primarily examined outcomes over a period of 52 weeks (about one year). Official research evidence notes that information concerning effects monitored over many years is limited.

Q: What is the official safety information about Cinqaero and liver problems?

Official information states that no dose adjustment is required for patients with mild hepatic impairment (minor liver problems). However, the medicine has not been studied in patients with severe hepatic impairment.

Q: Does Cinqaero have any effect on the immune system?

The drug's mechanism of action is targeted to the immune system by selectively reducing eosinophils, which are a type of white blood cell. Official safety data also reports that a small percentage of patients developed anti-reslizumab antibodies.

Q: Does the evidence show that Cinqaero helps reduce the number of asthma attacks?

Clinical studies report that adding Cinqaero to standard therapy was associated with statistically significant reductions in the annual frequency of asthma exacerbations compared to receiving a placebo. The outcome monitored in studies relates to the frequency of asthma exacerbations, which are phases of heightened symptom activity.

Q: Is Cinqaero widely available outside of hospitals?

As an intravenous infusion, Cinqaero must be administered by a healthcare professional in a healthcare setting. This setting is required to be prepared to manage potential hypersensitivity reactions.

Q: What should a patient do if they feel unwell after the infusion?

Patients are monitored during and for an appropriate period after the infusion is complete. Official patient information notes that patients should contact their healthcare professional immediately if they experience symptoms of an allergic reaction after the infusion.

Q: Does Cinqaero affect the ability to drive or operate machinery?

Official labeling provides information regarding functional effects and states that Cinqaero has no or negligible influence on the ability to drive or use machines.

Q: Is it safe to get a flu shot or other vaccines while on Cinqaero?

According to regulatory safety notes, the safety and efficacy of Cinqaero have not been established in patients concurrently receiving live vaccines.

Q: Are people who stop Cinqaero likely to have their symptoms return?

Research data regarding the duration of benefit after treatment is stopped is limited, which is noted as an area of research uncertainty in official documents.

Q: Is Cinqaero intended for long-term use?

Cinqaero is officially intended to be used as a long-term therapy option for severe asthma. A healthcare professional typically re-assesses the decision to continue the therapy at least annually.

Q: Are headaches a common complaint reported with Cinqaero?

Headaches are not listed as a Common, Uncommon, or Rare stand-alone adverse reaction in the official prescribing information for Cinqaero.

Q: Can Cinqaero be used in combination with other biologic asthma treatments?

Official documents state that the safety and efficacy profile in combination with other immunosuppressant medicines, including other biologic treatments for asthma, is unknown.

Q: Does Cinqaero cause changes to blood count results?

Reslizumab's mechanism of action is known to cause a rapid and sustained reduction in the number of circulating eosinophils, which is a specific type of white blood cell in the blood.

Q: Are there any specific organs Cinqaero might affect over time?

The official safety profile notes a documented concern regarding the occurrence of malignancy (cancer) that was observed in clinical studies.

Q: Can Cinqaero be administered at home?

Official documents describe that Cinqaero must be administered in a healthcare setting prepared to manage hypersensitivity reactions. It is not approved for administration in a patient's home.

Q: Does Cinqaero help with asthma symptoms caused by allergies?

Cinqaero is indicated specifically for the treatment of severe eosinophilic asthma and works by targeting eosinophils. Its indication is based on the presence of high eosinophil levels in the blood, not on the underlying cause of the asthma symptoms, such as specific allergies.

How to Store and Dispose of Cinqaero (Reslizumab)

The official storage and disposal requirements for Cinqaero are strictly regulated to maintain the product’s quality and stability.

Storage Requirements

Condition	Requirement
Temperature	Store the unopened vial in a refrigerator ( 2 C to 8 C).
Protection	Keep the vial in the outer carton to protect it from light.
Prohibitions	Do not freeze the vial. Do not shake the vial.
Post-Dilution	The diluted solution must be administered within 16 hours (whether stored at 2 C to 8 C or up to 25 C).
Safety	Keep this medicine out of the sight and reach of children.

Disposal Instructions

Cinqaero is a single-use product, and any remaining concentrate in the vial must be discarded immediately. Regulatory guidelines prohibit disposing of this medicine via wastewater or household trash. Patients and caregivers should consult a pharmacist for guidance on proper medical waste disposal to protect the environment.